- Home
- LPCN vs PMN Comparison
LPCN vs PMN Comparison
Compare LPCN & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- PMN
- Stock Information
- Founded
- LPCN 1997
- PMN 2004
- Country
- LPCN United States
- PMN Canada
- Employees
- LPCN N/A
- PMN N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- LPCN Health Care
- PMN Health Care
- Exchange
- LPCN Nasdaq
- PMN Nasdaq
- Market Cap
- LPCN 36.8M
- PMN 32.3M
- IPO Year
- LPCN N/A
- PMN N/A
- Fundamental
- Price
- LPCN $4.81
- PMN $0.96
- Analyst Decision
- LPCN Strong Buy
- PMN
- Analyst Count
- LPCN 1
- PMN 0
- Target Price
- LPCN $10.00
- PMN N/A
- AVG Volume (30 Days)
- LPCN 28.3K
- PMN 88.7K
- Earning Date
- LPCN 11-07-2024
- PMN 11-26-2024
- Dividend Yield
- LPCN N/A
- PMN N/A
- EPS Growth
- LPCN N/A
- PMN N/A
- EPS
- LPCN N/A
- PMN N/A
- Revenue
- LPCN $7,922,926.00
- PMN N/A
- Revenue This Year
- LPCN N/A
- PMN N/A
- Revenue Next Year
- LPCN N/A
- PMN N/A
- P/E Ratio
- LPCN N/A
- PMN N/A
- Revenue Growth
- LPCN N/A
- PMN N/A
- 52 Week Low
- LPCN $2.38
- PMN $0.92
- 52 Week High
- LPCN $11.79
- PMN $3.10
- Technical
- Relative Strength Index (RSI)
- LPCN 41.11
- PMN 41.92
- Support Level
- LPCN $4.64
- PMN $0.91
- Resistance Level
- LPCN $4.98
- PMN $1.08
- Average True Range (ATR)
- LPCN 0.51
- PMN 0.07
- MACD
- LPCN -0.12
- PMN -0.00
- Stochastic Oscillator
- LPCN 5.12
- PMN 19.23
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.